Dare Bioscience Inc at ROTH Conference Transcript
Thank you for joining us here today. I am Kumar Raja, Senior Biotech Analyst at ROTH MKM. The next company presenting is Daré Bioscience. We have Sabrina Martucci Johnson, who is the CEO and the President of the company.
Thanks, Sabrina, for joining us. Maybe we can just get started by just giving an overview of the company.
© -
(inaudible - microphone inaccessible) fertility and menopause, primarily. We have one FDA-approved product now in our portfolio and 10-plus in various stages of development. The late stage programs right now include that FDA-approved product, obviously, that we'll be launching first half of this year.
For condition called bacterial vaginosis we partnered with Organon. We have a Phase 3 program in contraception, first once-a-month hormone-free contraceptive candidate that's in development, and that's partnered with Bayer. And we're looking to start that Phase 3 this year.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |